Quarter ended 30 Sep 2026: consolidated revenue Rs 577.34 lakh versus Rs 278.69 lakh a year ago
MEDICAPQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Consolidated results for the quarter ended 30 September 2026 showed revenue from operations of Rs 577.34 lakh versus Rs 278.69 lakh in the same quarter a year earlier, up 107%, and a loss after tax of Rs 8.81 lakh versus Rs 223.29 lakh. Half-year consolidated revenue was Rs 856.04 lakh and net loss was Rs 232.12 lakh. Half-year operating cash flow was positive at Rs 170.65 lakh. Review found no material issue; prior figures were restated.
Revenue growth and a smaller quarterly loss are positive, but ongoing losses may weigh on sentiment despite positive operating cash flow.
The filed figures for this quarter have not reached us in XBRL yet, so there is nothing to compute here; the read above is the AI's, from the document. The table appears the moment the figures land.